A case of acute profound thrombocytopenia following abciximab therapy / 대한내과학회지
Korean Journal of Medicine
;
: 475-481, 2002.
Article
in Korean
| WPRIM
| ID: wpr-94618
ABSTRACT
Bleeding and thrombocytopenia are important adverse effects of abciximab. The incidence of abciximab-induced acute profound thrombocytopenia (APT) is low. APT is defined as an abrupt drop in platelet count to <20,000/microL that occurred within 24 hours of administration of an abciximab. This is distinct from all other types of drug-induced thrombocytopenia, which requires a period of drug administration to induce sensitization. If APT occurs and is left untreated, it can cause serious hemorrhage and ischemia that may be fatal. In this case, a 45-year-old man with acute myocardial infarction was administered a bolus intravenous injection of abciximab (0.25 mg/kg), followed by a 12-hour continuous infusion (10 microgram/min) during primary coronary angioplasty. We report a case of APT that was recognized at 2 hours after the initiation of abciximab infusion and was corrected without serious complications.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Platelet Count
/
Thrombocytopenia
/
Incidence
/
Angioplasty
/
Hemorrhage
/
Injections, Intravenous
/
Ischemia
/
Myocardial Infarction
Type of study:
Incidence study
/
Prognostic study
Limits:
Humans
Language:
Korean
Journal:
Korean Journal of Medicine
Year:
2002
Type:
Article
Similar
MEDLINE
...
LILACS
LIS